Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: A systematic review and meta-analysis

International Journal of Antimicrobial Agents

Volumn 44, Issue 6, 2014, Pages 477-485

  Gu, Wan Jie ^a   Wang, Fei ^b   Tang, Lu ^b   Bakker, Jan ^c   Liu, Jing Chen ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Colistin; Gram negative bacteria; Meta analysis; Multidrug resistant; Ventilator associated pneumonia

Indexed keywords

BETA LACTAM ANTIBIOTIC; CILASTATIN PLUS IMIPENEM; COLISTIN; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; ANTIINFECTIVE AGENT;

APNEA; BACTERIAL CLEARANCE; BRONCHOCONSTRICTION; CHEST TIGHTNESS; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; GRAM NEGATIVE BACTERIUM; HUMAN; INTENSIVE CARE; LENGTH OF STAY; LIVER TOXICITY; META ANALYSIS; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT GRAM NEGATIVE BACTERIUM; MUSCLE WEAKNESS; NEPHROTOXICITY; NEUROTOXICITY; REVIEW; SYSTEMATIC REVIEW; VENTILATOR ASSOCIATED PNEUMONIA; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; MICROBIOLOGY; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME;

EID: 84906801354     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.07.004     Document Type: Review

References (35)

1. J. Chastre, and J.Y. Fagon Ventilator-associated pneumonia Am J Respir Crit Care Med 165 2002 867 903
2. N. Bercault, and T. Boulain Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study Crit Care Med 29 2001 2303 2309
3. C.M. Parker, J. Kutsogiannis, J. Muscedere, D. Cook, P. Dodek, and A.G. Day Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes J Crit Care 23 2008 18 26
4. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, and L.B. Rice Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin Infect Dis 48 2009 1 12
5. J. Garnacho-Montero, C. Ortiz-Leyba, F.J. Jiménez-Jiménez, A.E. Barrero-Almodóvar, J.L. García-Garmendia, and M. Bernabeu-WittelI Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP Clin Infect Dis 36 2003 1111 1118
6. H. Kallel, L. Hergafi, M. Bahloul, A. Hakim, H. Dammak, and H. Chelly Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study Intensive Care Med 33 2007 1162 1167
7. F.G. Rios, C.M. Luna, B. Maskin, A. Saenz Valiente, M. Lloria, and S. Gando Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Eur Respir J 30 2007 307 313
8. A.P. Betrosian, F. Frantzeskaki, A. Xanthaki, and E.E. Douzinas Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia J Infect 56 2008 432 436
9. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, and D.J. Gavaghan Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
10. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. 〈http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp〉 [accessed 25 July 2014].
11. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
12. F. Song, A.J. Eastwood, S. Gilbody, L. Duley, and A.J. Sutton Publication and related biases Health Technol Assess 4 2000 1 115
13. N. Nakwan, J. Wannaro, T. Thongmak, P. Pornladnum, R. Saksawad, and N. Nakwan Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report Pediatr Pulmonol 46 2011 60 66
14. P. Rattanaumpawan, J. Lorsutthitham, P. Ungprasert, N. Angkasekwinai, and V. Thamlikitkul Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria J Antimicrob Chemother 65 2010 2645 2649
15. G. Kalin, E. Alp, R. Coskun, H. Demiraslan, K. Gündogan, and M. Doganay Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother 18 2012 872 877
16. Q. Lu, R. Luo, L. Bodin, J. Yang, N. Zahr, and A. Aubry Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii Anesthesiology 117 2012 1335 1347
17. R. Zalts, A. Neuberger, K. Hussein, A. Raz-Pasteur, Y. Geffen, and T. Mashiach Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam Am J Ther 2013 [Epub ahead of print]
18. D.P. Kofteridis, C. Alexopoulou, A. Valachis, S. Maraki, D. Dimopoulou, and D. Georgopoulos Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study Clin Infect Dis 51 2010 1238 1244
19. I.P. Korbila, A. Michalopoulos, P.I. Rafailidis, D. Nikita, G. Samonis, and M.E. Falagas Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study Clin Microbiol Infect 16 2010 1230 1236
20. M. Tumbarello, G. De Pascale, E.M. Trecarichi, S. De Martino, G. Bello, and R. Maviglia Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible Gram-negative bacteria Chest 144 2013 1768 1775
21. H.J. Jang, M.N. Kim, K. Lee, S.B. Hong, C.M. Lim, and Y. Koh The comparative efficacy of colistin monotherapy and combination therapy based on in vitro antimicrobial synergy in ventilator-associated pneumonia caused by multi-drug resistant Acinetobacter baumannii Tuberc Respir Dis 67 2009 212 220
22. F. Simsek, H. Gedik, M.T. Yildirmak, N.E. Iris, A. Türkmen, and A. Ersoy Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy? Indian J Med Microbiol 30 2012 448 452
23. H. Aydemir, D. Akduman, N. Piskin, F. Comert, E. Horuz, and A. Terzi Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia Epidemiol Infect 141 2013 1214 1222
24. G. Kalin, E. Alp, A. Akin, R. Coskun, and M. Doganay Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia Infection 42 2014 37 42
25. D.F. Florescu, F. Qiu, M.A. McCartan, C. Mindru, P.D. Fey, and A.C. Kalil What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression Clin Infect Dis 54 2012 670 680
26. R. Imberti, M. Cusato, P. Villani, L. Carnevale, G.A. Iotti, and M. Langer Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration Chest 138 2010 1333 1339
27. H.M. Arnold, A.M. Sawyer, and M.H. Kollef Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia Respir Care 57 2012 1226 1233
28. G.C. Wood Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia Expert Rev Anti Infect Ther 9 2011 993 1000
29. L. Dalfino, F. Puntillo, A. Mosca, R. Monno, M.L. Spada, and S. Coppolecchia High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study Clin Infect Dis 54 2012 1720 1726
30. S. Pournaras, G. Vrioni, E. Neou, J. Dendrinos, E. Dimitroulia, and A. Poulou Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay Int J Antimicrob Agents 37 2011 244 247
31. M. Tumbarello, P. Viale, C. Viscoli, E.M. Trecarichi, F. Tumietto, and A. Marchese Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy Clin Infect Dis 55 2012 943 950
32. M. Kempf, L. Djouhri-Bouktab, J.M. Brunel, D. Raoult, and J.M. Rolain Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii Int J Antimicrob Agents 39 2012 180 181
33. M. Nguile-Makao, J.R. Zahar, A. Français, A. Tabah, M. Garrouste-Orgeas, and B. Allaouchiche Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models Intensive Care Med 36 2010 781 789
34. P.J. Bergen, J. Li, and R.L. Nation Dosing of colistin - back to basic PK/PD Curr Opin Pharmacol 11 2011 464 469
35. C.A. Deryke, A.J. Crawford, N. Uddin, and M.R. Wallace Colistin dosing and nephrotoxicity in a large community teaching hospital Antimicrob Agents Chemother 54 2010 4503 4505